India has always been a pioneer in the drug design sector. Research methodology in modern chemistry, which is the foundation of drug design research has seen exponential growth in the country. India has seen an upswing in commercialization since the Indian markets opened up for the world in 1991. Hence, India is now a major player in the drug design field.
A recent example of India’s dominance in drug design research is Serum Institute’s and Bharat Biotech’s COVID-19 vaccines. The vaccines are found to be effective against most of the variants.
Objectives of drug design and development
The aim of the drug discovery and development process is to identify the compounds with desired pharmacological properties in order to treat the diseases more efficiently and effectively.
Evolution of drug design in Indian pharma industry
The Indian pharma industry is a global leader in the production of high-quality generic drugs. India is ranked third in manufacturing pharma products by volume. The change in the regulatory policies in 2005 allowed many players to explore the drug discovery space. Public-Private Partnership (PPP) models came into existence. Indian pharma companies with deep pockets and research capabilities invested in building research infrastructure.
As of now Indian pharma companies are working on more than 120 new chemical entities (NCEs) in various preclinical and clinical stages of development.
JaysMedLab: New Kid on the block
There are many new companies, doing some remarkable work in the field of drug design research. One company that stands out of the lot is JaysMedLab. Started in 2009 by Jayadev Shastri, a molecular design scientist, JaysMedLab is a research-oriented pharma company. The company has three divisions- drug design, distribution, and testing of raw drugs/herbs.
In 2019, the company changed its name to JaysMedLabs with the aim to diversify into drug design.
More about JaysMedLab and its founder
The founder of JaysMedLab, Jayadev Shastri is a molecular design scientist himself. This gives the company a huge advantage in terms of subject matter expertise. Shastri has developed an anticancer molecule and will approach the concerned authorities to run clinical trials. He is right now working on 4 different molecules, three of them with the potential to treat HIV. He is planning to invest over $20,000 from his resources and seeking to raise over $100,000 to $300,000. The company’s main focus is currently to make the lab fully functional.
